Clinical Study

Long-Term Results after Treatment of Very Low-, Low-, and High-Risk Thyroid Cancers in a Combined Setting of Thyroidectomy and Radio Ablation Therapy in Euthyroidism

Nikos Emmanouilidis, Harald Schrem, Michael Winkler, Jürgen Klempnauer, and Georg F. W. Scheumann

Allgemein- , Viszeral- und Transplantationschirurgie, Hannover Medical School, Carl-Neuberg Straße 1, 30625 Hannover, Germany

Correspondence should be addressed to Nikos Emmanouilidis; emmanouilidis.nikos@mh-hannover.de

Received 21 February 2013; Revised 17 June 2013; Accepted 17 June 2013

Academic Editor: Jack R. Wall

Copyright © 2013 Nikos Emmanouilidis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Differentiated thyroid cancer treatment usually consists of thyroidectomy and radio ablation in hypothyroidism 4-6 weeks after surgery. Replacing hypothyroidism by recombinant human thyroid stimulating hormone can facilitate radio ablation in euthyroidism within one week after surgery. The outcome of this approach was investigated.

Methods. This is a prospective randomized trial to compare thyroidectomy and radio ablation within a few days after preconditioning with recombinant human thyroid stimulating hormone versus thyroidectomy and radio ablation separated by four weeks of L-T4 withdrawal. Tumors were graded into very low-, low-, or high-risk tumors. Recurrence-free survival was confirmed at follow-up controls by neck ultrasound and serum thyroglobulin. Suspected tumor recurrence was treated by additional radio ablation or surgery. Quality-of-life questionnaires with additional evaluation of job performance and sick-leave time were used in all patients.

Results. Radio ablation in euthyroidism in quick succession after thyroidectomy did not lead to higher tumor recurrence rates of differentiated thyroid cancers in any risk category and was significantly advantageous with respect to quality-of-life (P < 0.001), sick-leave time (P < 0.001), and job performance (P = 0.002). Conclusion. Recombinant human thyroid stimulating hormone can be used safely and with good efficacy to allow radio ablation under sustained euthyroidism within one week after thyroidectomy.

1. Introduction

The standard treatment for differentiated thyroid cancer (DTC) consists of thyroidectomy followed by radio ablation therapy (RAT) [1–3]. For RAT an elevated thyrotropin (TSH) serum level of at least 30 mU/L is necessary to have a sufficient 131I uptake into remnant thyroid tissue. TSH levels of 30 mU/L and higher can be achieved either by complete thyroidectomy and four weeks of the L-T4 hormone withdrawal or by exogenous substitution of recombinant human TSH (rhTSH). If patients are preconditioned by L-T4 withdrawal, they have to cope with the increasing symptoms of hypothyroidism and the concurrent negative socioeconomic side effects [4–7]. The ability to substitute pituitary TSH by recombinant TSH uncouples the radio ablative treatment (RAT) from hypothyroidism and facilitates RAT in euthyroidism under full-scale L-T4 substitutive medication. The socioeconomic advantages of RAT in euthyroidism are a sustained quality-of-life and a significantly reduced number of sick-leave days [4, 8, 9] and it has been shown that rhTSH preconditioning is as effective and safe as preconditioning by hypothyroidism [10–13].

Here we present long-term follow-up data of a randomized clinical trial comparing the efficacy of RAT after preconditioning by rhTSH with hypothyroidism. In addition, we have measured and compared the impact of both competing strategies of preconditioning by rhTSH or hypothyroidism on quality-of-life and job performance.

2. Subjects and Methods

2.1. Study Patients. Forty-four patients with a diagnosis of DTC (Table 1) gave written informed consent to participate in the study, which was approved by the institutional
Table 1

| Clinical data of all patients | rhTSH | Hypothyroidism | P* |
|-------------------------------|-------|----------------|----|
| Gender (M/F)                  | 6/18  | 5/15           | n.s.|
| Age [yrs.] (mean, median, range) | 47, 50, 17–66 | 56, 58, 30–73 | n.s.|
| Tumor histology (PTC/FTC)     | 22/2  | 19/1           | n.s.|
| Tumor size [mm] (mean, median, range) | 20.4, 20.0, 1–60 | 10.3, 8.5, 1.5–30 | <0.01|
| pT                            |       |                |     |
| 1a                            | 5     | 10             | n.s.|
| 1b                            | 8     | 7              | n.s.|
| 2                             | 5     | 1              | n.s.|
| 3                             | 6     | 2              | n.s.|
| pN                            |       |                |     |
| X                             | 4     | 0              | n.s.|
| 0                             | 10    | 11             | n.s.|
| 1                             | 10    | 9              | n.s.|
| pM                            |       |                |     |
| X                             | 23    | 20             | n.s.|
| 1                             | 1     | 0              | n.s.|
| UICC 2002 staging             |       |                |     |
| X                             | 4     | 0              | n.s.|
| I                             | 13    | 13             | n.s.|
| II                            | 0     | 0              | n.s.|
| III                           | 5     | 5              | n.s.|
| IVA                           | 1     | 2              | n.s.|
| IVB                           | 0     | 0              | n.s.|
| IVC                           | 1     | 0              | n.s.|
| Risk category                 |       |                |     |
| High                          | 12    | 11             | n.s.|
| Low                           | 4     | 4              | n.s.|
| Very low                      | 5     | 5              | n.s.|
| Sick leave* from surgery to first RAT (Days) | 4, 0, 0–23 | 41, 28, 4–150 | <0.001|

* Mann-Whitney U test or Pearson $\chi^2$ statistics applied where appropriate.

2.2. Questionnaire. All patients had to complete a questionnaire at five weeks after surgery. The questionnaire's main targets were clinical symptoms such as fatigue/lethargy, lack of concentration, disturbance of sleep/insomnia, intolerance to cold, rough skin, and slowed movements. Possible answers were no, light, medium, strong, very strong, or not specified (e.g., pensioner). Housewives were asked to answer other than not specified (n.s.) (Table 3).

2.3. Recombinant Human Thyrotropin. RhTSH (Thyrogen, Genzyme, Cambridge, Mass.) with a biological potency of 10 U/mg of protein was used according to the manufacturer’s instructions. Each vial containing 0.9 mg of rhTSH-alpha was dissolved in 1.2 mL of water for injection and administered by the i.m. route to the gluteal region 48 h before RAT.

2.4. Radio Ablative Treatment (RAT). After iodine uptake was confirmed by neck scan with 100 Milli-Becquerel (MBq) $^{131}$I, the ablative activity of 3700 MBq $^{131}$I was administered orally.

2.5. Laboratory Measurements. Serum levels of thyroxin ($T_4$), 3,5,3'-triiodothyronine ($T_3$), TSH, thyroglobulin (Tg), urinary iodine excretion, and urinary creatinine were measured on examination days.

2.6. Scintigraphy. Whole body scans and scans of the neck region were conducted before RAT, at the time of RAT, and at three and twelve months after surgery in both groups with and without rhTSH. Additional scans were performed depending on the results of US examinations and Tg readings (Table 2). Scans at follow-up controls were performed after L-T$_4$ withdrawal and using 100 to 600 MBq of $^{131}$I. Ablation was considered to be successful if less than 2.0% of the applied activity was taken up in the thyroid bed (TB) and no extrathyroidal uptake was noted. If a local DTC recurrence was suspected, for example, due to elevated Tg levels or due to ultrasound examination, a patient would receive an ablative activity of 3700 MBq $^{131}$I, even if the diagnostic scintigraphy beforehand was negative for tumor recurrence. Thus, diagnostic scans in these cases were performed using higher activities than the standard 100–600 MBq.

2.7. Ultrasound. Ultrasound (US) of the neck region was carried out at the time of RAT, at three- and twelve-month intervals after surgery, and subsequently at each follow-up examination. If the US revealed suspiciously enlarged lymph
Table 2: Follow-up data of all patients.

| Pat. | # UICC 2002 | Risk | Follow-up I | Follow-up II | Follow-up III | Follow-up IV | Follow-up V | Follow-up VI | Follow-up VII |
|------|-------------|------|-------------|-------------|--------------|-------------|-------------|--------------|--------------|
|      |             |      | Reccur. Therapy | Reccur. Therapy | Reccur. Therapy | Reccur. Therapy | Reccur. Therapy | Reccur. Therapy | Reccur. Therapy |
| 11   | I           | X    | 4            | No           | 12            | No           | 19          | No           | 32           | 44           | 55           | No          |
| 23   | X           | X    | 3            | No           | 10            | No           | f           |              |              |              |              |             |
| 24   | X           | X    | 3            | No           | 5             | No           | 13          | No           | 20          | No           | f            |             |
| 3    | I           | Very low | 3          | No           | 12            | No           | p           |              | p            |              | p            | 64 No       |
| 4    | I           | Very low | 4          | No           | 13            | No           | p           |              | p            |              | p            | 63 No       |
| 13   | I           | Very low | 3          | No           | 13            | No           | 20          | No           | 29          | No           | 37 No       | 47 No       | 61 No       |
| 15   | I           | Very low | 2          | No           | 13            | No           | 24          | No           | 38          | No           | f            |             |
| 18   | I           | Very low | 4          | No           | 12            | No           | 18          | No           | 30          | No           | P            | 54 No       | f            |
| 5    | I           | Low    | 4           | No           | 12            | No           | p           |              | p            |              | p            | 66 No       |
| 8    | I           | Low    | 3           | No           | p             |              | p           |              | p            |              | p            | 64 No       |
| 14   | X           | Low    | 4           | No           | 13            | No           | p           |              | p            |              | p            | 44 No       | f            |
| 17   | I           | Low    | SAE         | No           |               |              |              |              |              |              |              |             |
| 1    | I           | High   | 4           | No           | 12            | No           | 26          | No           | 38          | No           | 50 No       | 59 No       | 85 No       |
| 2    | III         | High   | 3           | No           | 13            | No           | 18          | No           | 32          | No           | 38 No       | 44 No       | 82 No       |
| 6    | III         | High   | 4           | No           | 12            | No           | 28          | No           | 37          | No           | f            |             |
| 7    | III         | High   | 3 sus RAT   | 10           | No           | 28 LN Surg   | 36 TB Surg  | 36 oss Surg | 36 oss Surg | 56 oss Surg | 56 oss Surg | 59 oss Surg |
| 9    | I           | High   | 4           | No           | 12            | No           | 19          | No           | 36          | No           | 39 No       | 50 No       | 69 No       |
| 10   | IVA         | High   | 4 sus RAT   | 8           | No           | 17 sus RAT   | 25 sus RAT  | 25 sus RAT  | 38          | No           | 57 No       | 72 No       |             |
| 11   | I           | Very low | 4          | No           | 11            | No           | p           |              | p            |              | 43 No       | f            |             |
| 19   | X           | High   | AE          | No           |               |              |              |              |              |              |              |             |
| 20   | IVC         | High   | AE          | No           |               |              |              |              |              |              |              |             |
| 21   | III         | High   | 3           | No           | 12            | No           | 16          | No           | 24          | No           | 30 No       | 42 No       | f            |
| 22   | III         | High   | 3           | No           | 11            | No           | 24          | No           | f            |              |              |             |
| 1    | I           | Very low | 4          | No           | 7             | No           | 11          | No           | 20          | No           | 29 No       | 41 No       | f            |
| 3    | I           | Very low | 4          | No           | 12            | No           | p           |              | p            |              | 53 No       | f            |             |
| 9    | I           | Very low | 3          | No           | 10            | No           | 21          | No           | 28          | No           | 36 No       | 40 No       | 66 No       |
| 10   | I           | Very low | 4 sus RAT  | 9           | No           | 21 sus RAT  | 24 sus RAT | 24 sus RAT | f            |              |             |             |
| 15   | I           | Very low | AE          |              |              |              |              |              |              |              |              |             |
| 4    | I           | Low    | 3           | No           | 14            | No           | 27          | No           | df           |              |              |             |
| 12   | I           | Low    | 4           | No           | 12            | No           | 30          | No           | f            |              |              |              |
| 13   | I           | Low    | 3           | No           | 12            | No           | 19          | No           | 32          | No           | 45 No       | 56 No       | f            |
| 17   | I           | Low    | 3           | No           | 12            | No           | 18          | No           | f            |              | 45 No       | f            |             |
| 2    | I           | High   | 3           | No           | 13            | No           | 25          | No           | 32          | No           | 44 No       | 57 No       | f            |
| 5    | III         | High   | 4 sus RAT  | 8           | No           | 16 sus RAT  | 40 sus RAT | 40 sus RAT | f            |              |              |             |
| 6    | IVA         | High   | 4 No        | 8           | No           | 13 sus RAT  | 21 sus RAT | 46 sus RAT | 46 No       | 59 No       | f            | 62 No       |
| 7    | IVA         | High   | 4 sus RAT  | 12 sus RAT  | 18 sus RAT   | 25 sus RAT  | 32 sus RAT | 32 sus RAT | f            |              | 63 No       |             |
| 8    | I           | High   | 4 No        | 9           | No           | 28 sus RAT  | 37 sus RAT | 43 sus RAT | 43 sus RAT | 53 No       | 66 No       |             |
| 11   | III         | High   | 4 sus RAT  | 8           | No           | 24 sus RAT  | 30 sus RAT | 30 sus RAT | 50 No       | 50 No       | 62 No       |             |
| 14   | I           | High   | 4 sus RAT  | 9           | No           | 18 sus RAT  | 37 sus RAT | 37 sus RAT | 37 sus RAT | 43 No       | 63 No       |             |
| 16   | III         | High   | df          |             |              |              |              |              |              |              |              |             |
| 18   | I           | High   | 3           | No           | 12            | No           | 20          | No           | 27          | No           | f            |             |
| 19   | III         | High   | 4           | No           | 12            | No           | 16          | No           | 23          | No           | 37          | 43 No       | 55 No       |
| 20   | III         | High   | 4           | No           | 12            | No           | 18          | No           | 32          | No           | 38 No       | f            |             |

RAT: additional radio ablation therapy, Surg: surgery, sus: suspicion for tumor recurrence, LN: lymph node, oss: bone, TB: thyroid bed, AE: adverse event (e.g., protocol violation), SAE: serious adverse event (surgical complication), df: discontinued follow-up, f: follow-up in progress, p: patient did not show up for follow-up, Recurr.: tumor recurrence.
2.8. Statistical Analysis. Statistical analysis was performed using IBM SPSS Statistics Ver.20 and Analyse-it for Microsoft Excel (version 2.00) (Analyse-it Software, Ltd. http://analyse-it.com/; 2007). Distribution for normality was tested on descriptive statistics. A nonparametric U-test (Mann-Whitney U test) was performed to test the significance of the underlying hypothesis. Survival data and tumor recurrence data were analyzed by Kaplan-Meier statistics and groups were compared using the Log Rank test.

3. Results

Patients were followed up for an average period of 52 months (median = 56 months; SE ± 2.8) (see also Table 2). In rhTSH receivers one patient had to be censored for the analysis of the quality-of-life queries due to a postoperative complication and prolonged postoperative weaning (see Table 3). With respect to the evaluation of therapy effectiveness three patients from rhTSH receivers and two patients of the hypothyroidism group had to be censored (see Table 2).

In the group of rhTSH receivers, 13 (62%) patients were employees, 4 (19%) were housewives, and 4 (19%) pensioners. In the L-T4 abstinence group 9 (50%) patients were employees, 5 (28%) were housewives, and 4 (22%) patients were pensioners.

The mean tumor size for rhTSH receivers was 20.4 mm (SD ± 14.4 mm), with one measurement for tumor size missing. The mean tumor size in patients preconditioned by L-T4 abstinence was 10.3 mm (SD ± 7.1 mm). Twenty-two rhTSH receivers had a histology of papillary differentiated carcinoma (PTC) and two had a follicular differentiation (FTC). In the hypothyroidism group eighteen patients had a PTC and two patients had a FTC. The rhTSH group and the hypothyroidism group had an equal distribution of high-risk, low-risk, very low-risk, and nonspecifiable-risk (X) tumors (Table 1).

DTC recurrence was suspected in three rhTSH receivers and four patients after hypothyroidism (Figures 1(a) and 1(b)). Those patients with a suspected DTC recurrence were treated by an additional course of RAT. But only in one patient (rhTSH group) DTC recurrence proved to be true after surgery and histological examination of a supraclavicular lymph node (Figure 1(c)). This patient also received an additional surgical procedure due to bone metastases. One patient died during follow-up without a suspected or a histological proven DTC (Figure 1(d)). Comparing preconditioning by rhTSH or hypothyroidism there was neither a statistically significant difference in numbers of suspected or histological proven DTC recurrences nor any significant difference in overall survival (Log Rank P > 0.05) (Figure 1).

The average time interval from surgery to primary ablation was 7.3 days for rhTSH receivers (SD ± 2.5; median = 7) and 31.4 days for patients preconditioned by hypothyroidism (SD ± 6.6; median = 31) (P < 0.0001). The average time interval from surgery to discharge from hospital after initial RAT was 10.1 days (SD ± 2.4; median = 9) for rhTSH receivers and 36.2 days (SD ± 4.7; median = 35) for hypothyroidism patients (P < 0.0001). The average sick-leave time for rhTSH receivers was 4.8 days (SD ± 7.2; median = 0) and 40.7 days (SD ± 44.5; median = 28) for patients in the hypothyroidism group (P = 0.0350) (Table 1). Three patients in the rhTSH group reported sick-leave time after initial RAT and discharge from hospital: patient 3 reported 23 days of sick-leave time due to a necessary hospitalization not related to the DTC therapy, patient 11 reported 14 days of sick leave time, related to symptoms of hypocalcaemia; patient 6 reported 4 days of sick-leave time, related to a transient alteration of her voice and her job affiliation as a teacher. In contrast, all sick leaves of hypothyroidism patients were related to symptoms of hypothyroidism and no patient of this group reported any sick leave after the initial RAT.

Patients preconditioned by rhTSH experienced significantly fewer clinical symptoms in comparison to patients preconditioned by hypothyroidism (Table 3 and Figure 2). Almost all patients of the hypothyroidism group reported fatigue or lethargy (18/20; 90%), while only three patients of the rhTSH group (13%) experienced such symptoms. Two thirds (12/20; 60%) of the patients preconditioned by hypothyroidism experienced lack of concentration compared to only one patient of the rhTSH group (4%).

| Clinical symptoms | rhTSH | Hypothyroidism |
|-------------------|-------|----------------|
| Gain in weight    | 6     | 14             |
| Fatigue/lethargy | 9     | 33             |
| Laps of concentration | 5     | 20             |
| Disorder of sleep/insomnia | 10    | 14             |
| Intolerance to cold | 9    | 16             |
| Constipation      | 5     | 15             |
| Cold skin         | 1     | 10             |
| Rough skin        | 5     | 17             |
| Slowed movements  | 6     | 13             |
| Periorbital edema | 2     | 13             |
| Peripheral edema  | 0     | 4              |

Mann-Whitney’s statistic 113.0
Z statistic
2-tailed P 0.0002 (exact tables used, 27% ties)

| Points per symptom | Avrg. points per symptom and patient | Points per symptom | Avrg. points per symptom and patient |
|--------------------|-------------------------------------|--------------------|-------------------------------------|
| Gain in weight     | 6.0 ± 0.27                          | 14.0 ± 0.74        |
| Fatigue/lethargy   | 9.0 ± 0.41                          | 33.0 ± 1.65        |
| Laps of concentration | 5.0 ± 0.23                        | 20.0 ± 1.00        |
| Disorder of sleep/insomnia | 10.0 ± 0.45         | 14.0 ± 0.70        |
| Intolerance to cold | 9.0 ± 0.41                         | 16.0 ± 0.80        |
| Constipation       | 5.0 ± 0.23                          | 15.0 ± 0.75        |
| Cold skin          | 1.0 ± 0.05                          | 10.0 ± 0.53        |
| Rough skin         | 5.0 ± 0.25                          | 17.0 ± 0.94        |
| Slowed movements   | 6.0 ± 0.30                          | 13.0 ± 0.68        |
| Periorbital edema  | 2.0 ± 0.10                          | 13.0 ± 0.68        |
| Peripheral edema   | 0.0 ± 0.00                          | 4.0 ± 0.22         |

Avrg. points per symptom, patient, and study arm

International Journal of Endocrinology
Figure 1: DTC-recurrence and patient survival. Statistically there was no significant difference in numbers of suspected DTC recurrences in (a) low/very low and (b) high-risk DTC categories as well (Log Rank $P = 0.317$; Log Rank $P = 0.761$, resp.). (c) Histological evidence (lymph node and bone metastasis) for DTC recurrence was found only in one case. (d) There was no difference in patient survival (Log Rank $P = 0.299$). One patient of the hypothyroidism group died due to natural cause. Prior to death this patient had neither a suspected nor histological proven DTC recurrence.

About one third of hypothyroidism patients experienced intolerance to cold, gain in weight, disorder of sleep, constipation, and periorbital edema which were reported by one third of the patients of the hypothyroidism group (6/20; 30% each). Cold skin was documented by four hypothyroidism patients (4/20; 20%).

While intolerance to cold and disorder of sleep were each reported by four rhTSH patients (4/23; 17%), the symptoms gain in weight (1/23), constipation (1/23), dry skin (2/23), and slowed down movements (2/23) were not reported in significant numbers. Cold skin and periorbital edema were not mentioned in the rhTSH protocol group at all.

In contrast to the patients of the rhTSH group, who reported that their treatment for thyroid cancer had no or only little impact on their job performance up to 5 weeks after surgery, nearly all patients of the hypothyroidism group—except three patients—reported a significant negative impact on their ability to maintain regular job performance (Table 4), which ultimately led to a significant increase of sick-leave days (Table 1).
4. Discussion

Today’s standard in treatment of differentiated thyroid cancer (DTC) is a combination of thyroidectomy followed by radioablation therapy (RAT) [1–3]. To which extent the thyroid gland should be removed—total thyroidectomy versus a more limited thyroid resection and whether a central lymphadenectomy should be performed or not—is an on-going controversy [14,15]. The benefit of RAT for a DTC recurrence-free survival though is undisputed. Before recombinant human TSH was available, the only way to achieve elevated thyrotropin levels for RAT was by thyroid-hormone abstinence after thyroidectomy. But hypothyroidism also meant that patients had to endure the debility and fatigue of a slowly developing hypothyroidism during this period [4–7]. Contrary, if a patient is preconditioned by rhTSH then L-T₄-medication can be continued and RAT can be conducted in euthyroidism [6, 8, 11, 12, 16, 17]. Maintaining euthyroidism is not only beneficial to avoid the negative clinical symptoms of hypothyroidism and to avoid additional disadvantageous socioeconomic side effects, but is also beneficial for a normal wound-healing process [18–20]. Hence, from a patient’s point of view it is understandable that rhTSH is favoured over L-T₄ withdrawal when it comes to preconditioning for RAT. Nonetheless, the final long-term oncological outcome of the respective therapeutic strategy (rhTSH or L-T₄ withdrawal) is still decisive for the choice of a treatment strategy for thyroid cancer.

In our clinic it was a common procedure that patients with a diagnose of DTC would receive their first RAT after a postoperative L-T₄-abstinence period. This strategy was maintained until we had tested a shortened treatment protocol that utilizes rhTSH and merges surgery and radioablation therapy into one hospitalization period. When preconditioned by rhTSH, the consecutive primary RAT can be initiated within one week after thyroidectomy. This procedure was then compared to the common procedure of preconditioning by 4–6 weeks of L-T₄-abstinence. In the initial study
[21] we found that the lion’s share of possible reduction of sick-leave time lies within the period from surgery to RAT. We also found that this improvement was achievable without any cut-backs on safety or ablation efficacy.

Now, seven years after study initiation we report our long-term follow-up data of all 44 patients with the diagnosis of DTC (including \( n = 23 \) patients with high-risk tumors) who were prospectively randomized for either preconditioning by rhTSH or hypothyroidism. We have not found any significant difference between both preconditioning strategies with respect to DTC recurrence or survival, neither for the low/very low nor for the high-risk tumor categories (Figure 1) \((\text{Log Rank } P = 0.317; \text{Log Rank } P = 0.761, \text{resp.})\). The overall incidence of suspected DTC recurrences was comparable for both treatment strategies. As expected, the incidence of suspected DTC recurrence was a little higher for high-risk tumors as compared to the low/very low risk category (Figures 1(a) and 1(b)). We also confirm the possible cut-backs on safety and ablation efficacy for high-risk tumors as compared to the low/very low risk category. The quick succession after thyroidectomy should be the standard procedure in the initial treatment of DTC—regardless of the DTC risk category.

### 5. Conclusion

We conclude that RAT after rhTSH preconditioning and in quick succession after thyroidectomy should be the standard procedure in the initial treatment of DTC—regardless of the DTC risk category.

### Conflict of Interests

All authors declare that there is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

### Disclosure

Thyrogen medication was provided by Genzyme Corp. Other than Thyrogen medication there was no financial support or other support whatsoever by internal, external, government or industry.

### Acknowledgment

We acknowledge support by Deutsche Forschungs-Gemeinschaft (DFG).

### References

[1] E. L. Mazzaferri, “An overview of the management of papillary and follicular thyroid carcinoma,” *Thyroid*, vol. 9, no. 5, pp. 421–427, 1999.

[2] M. J. Schlumberger, “Papillary and follicular thyroid carcinoma,” *The New England Journal of Medicine*, vol. 338, no. 5, pp. 297–306, 1998.

[3] L. J. DeGroot, E. L. Kaplan, M. McCormick, and F. H. Straus, “Natural history, treatment, and course of papillary thyroid carcinoma,” *Journal of Clinical Endocrinology and Metabolism*, vol. 71, no. 2, pp. 414–424, 1990.

[4] D. C. Sweeney and G. S. Johnston, “Radioiodine therapy for thyroid cancer,” *Endocrinology and Metabolism Clinics of North America*, vol. 24, no. 4, pp. 803–839, 1995.

[5] K. H. Dow, B. R. Ferrer, and C. Anello, “Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy,” *Thyroid*, vol. 7, no. 4, pp. 613–619, 1997.

[6] M. Luster, R. Felbinger, M. Dietlein, and C. Reiners, “Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration,” *Thyroid*, vol. 15, no. 10, pp. 1147–1155, 2005.

[7] T. Davids, I. J. Witterick, S. Eski, P. G. Walish, and J. L. Freeman, “Three-week thyroxine withdrawal: a thyroid-specific quality of life study,” *Laryngoscope*, vol. 116, no. 2, pp. 250–253, 2006.

[8] I. Borget, C. Corone, M. Nocaudie et al., “Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal,” *International Journal of Endocrinology*, 2011.
[9] I. Borget, H. Remy, J. Chevalier et al., “Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 35, no. 8, pp. 1457–1463, 2008.

[10] S. Kohlfuerst, I. Igerc, and P. Lind, “Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine,” *Thyroid*, vol. 15, no. 4, pp. 371–376, 2005.

[11] C. A. Meier, L. E. Braverman, S. A. Ebner et al., “Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study),” *Journal of Clinical Endocrinology and Metabolism*, vol. 78, no. 1, pp. 188–196, 1994.

[12] P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri et al., “Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma,” *The New England Journal of Medicine*, vol. 337, no. 13, pp. 888–896, 1997.

[13] B. R. Haugen, F. Pacini, C. Reiners et al., “A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer,” *Journal of Clinical Endocrinology and Metabolism*, vol. 84, no. 11, pp. 3877–3885, 1999.

[14] P. A. Singer, D. S. Cooper, G. H. Daniels et al., “Guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association,” *Archives of Internal Medicine*, vol. 156, no. 19, pp. 2165–2172, 1996.

[15] B. L. Solomon, L. Wartofsky, and K. D. Burman, “Current trends in the management of well differentiated papillary thyroid carcinoma,” *Journal of Clinical Endocrinology and Metabolism*, vol. 81, no. 1, pp. 333–339, 1996.

[16] P. Mernagh, S. Campbell, M. Dietlein, M. Luster, E. Mazzaferri, and A. R. Weston, “Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective,” *European Journal of Endocrinology*, vol. 155, no. 3, pp. 405–414, 2006.

[17] P. R. Schroeder, B. R. Haugen, F. Pacini et al., “A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal,” *Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 3, pp. 878–884, 2006.

[18] M. D. L. P. Biondo-Simões, S. O. Ioshii, K. S. Borsato, and E. Zimmermann, “The healing process influenced by hypothyroidism and by elderly. Study of abdominal wall healing in rats,” *Acta Cirúrgica Brasileira*, vol. 20, supplement 1, pp. 211–219, 2005.

[19] J. Natori, K. Shimizu, M. Nagahama, and S. Tanaka, “The influence of hypothyroidism on wound healing. An experimental study,” *Nippon Ika Daigaku Zasshi*, vol. 66, no. 3, pp. 176–180, 1999.

[20] J. D. Safer, T. M. Crawford, and M. F. Holick, “A role for thyroid hormone in wound healing through keratin gene expression,” *Endocrinology*, vol. 145, no. 5, pp. 2357–2361, 2004.

[21] N. Emmanouilidis, J. A. Müller, M. D. Jäger et al., “Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH,” *European Journal of Endocrinology*, vol. 161, no. 5, pp. 763–769, 2009.